The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition
<p>Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Codon Publications
2017-05-01
|
| Series: | Journal of Kidney Cancer and VHL |
| Subjects: | |
| Online Access: | http://jkcvhl.com/index.php/jkcvhl/article/view/69 |
| Summary: | <p>Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding existing data on subsequent therapies is crucial to define an optimal treatment sequence following first-line failure. This review examines the data supporting currently approved agents in this setting and provides a framework for decision-making regarding treatment sequencing beyond first-line therapy with VEGFR TKIs.</p> |
|---|---|
| ISSN: | 2203-5826 |